Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06609174 · ClinicalTrials.gov registry record · NA
AI-SCREENDCM Decentralized Clinical Trial - Pilot Study
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 119
- Enrollment target
NCT06609174: Completed NA study, sponsored by Mayo Clinic.
NCT06609174 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 119 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06609174, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 119 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the feasibility and impact of screening FDR of DCM probands using a mobile ECG with the ability to transmit the ECG for cloud-based AI analysis to detect reduced left ventricular ejection fraction (LVEF). This protocol will examine the impact of incorporating the screening AI enhanced ECG into standard of care recommendations.
Primary Outcome
Measured by the number of complete transmissions from the Kardia 6-lead device to the AI-ECG algorithm.
Interventions
- DIAGNOSTIC_TEST KardiaRx ECG Screening and AI interpretation of ECG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2024-10-18 |
| Est. Completion | 2025-09-26 |
| Phase | NA |
What the finished NCT06609174 record still lists
NCT06609174 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which KardiaRx ECG Screening and AI interpretation of ECG is the first listed.
NCT06609174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06609174 about?
NCT06609174 is a clinical study titled "AI-SCREENDCM Decentralized Clinical Trial - Pilot Study". The purpose of this study is to assess the feasibility and impact of screening FDR of DCM probands using a mobile ECG with the ability to transmit the ECG for cloud-based AI analysis to detect reduced left ventricular ejection fraction (LVEF). This protocol will examine the impact of incorporating t...
What is the current status of trial NCT06609174?
This trial is currently completed. It is a NA study. The enrollment target is 119 participants. The study started on 2024-10-18. Estimated completion is 2025-09-26.
What interventions are being tested in trial NCT06609174?
The interventions under investigation include: KardiaRx ECG Screening and AI interpretation of ECG (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06609174?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06609174's enrollment target sits among peer trials
119 803rd of 2000 higher than 1,198 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI